Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300

被引：21

作者：

Lai, Kwong Wah ^{[1
]}

Romero, F. Anthony ^{[2
]}

Tsui, Vickie ^{[2
]}

Beresini, Maureen H. ^{[2
]}

Boenig, Gladys de Leon ^{[2
]}

Bronner, Sarah M. ^{[2
]}

Chen, Kevin ^{[1
]}

Chen, Zhongguo ^{[1
]}

Choo, Edna F. ^{[2
]}

Crawford, Terry D. ^{[2
]}

Cyr, Patrick ^{[2
]}

Kaufman, Susan ^{[2
]}

Li, Yingjie ^{[1
]}

Liao, Jiangpeng ^{[1
]}

Liu, Wenfeng ^{[1
]}

Ly, Justin ^{[2
]}

Murray, Jeremy ^{[2
]}

Shen, Weichao ^{[1
]}

Wai, John ^{[1
]}

Wang, Fei ^{[1
]}

Zhu, Caicai ^{[1
]}

Zhu, Xiaoyu ^{[1
]}

Magnuson, Steven ^{[2
]}

机构：

[1] WuXi AppTec Co Ltd, 288 Fute Zhong Rd, Shanghai 200131, Peoples R China

[2] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2018年 / 28卷 / 01期

关键词：

Bromodomain; CBP inhibitor; Volume of distribution; Half-life; CREB-BINDING-PROTEIN; CBP; COACTIVATOR; ACETYLATION; P300; DOMAIN;

D O I：

10.1016/j.bmcl.2017.11.025

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel, potent, and orally bioavailable inhibitor of the bromodomain of CBP, compound 35 (GNE-207), has been identified through SAR investigations focused on optimizing al bicyclic heteroarene to replace the aniline present in the published GNE-272 series. Compound 35 has excellent CBP potency ( CBP IC50 = 1 nM, MYC EC50 = 18 nM), a selectively index of > 2500-fold against BRD4(1), and exhibits a good pharmacokinetic profile. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：15 / 23

页数：9

共 50 条

[1] Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains
Brennan, P.E. (paul.brennan@sgc.ox.ac.uk), 1600, American Chemical Society (136):
[2] Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
Hay, Duncan A.
Fedorov, Oleg
Martin, Sarah
Singleton, Dean C.
Tallant, Cynthia
Wells, Christopher
Picaud, Sarah
Philpott, Martin
Monteiro, Octovia P.
Rogers, Catherine M.
Conway, Stuart J.
Rooney, Timothy P. C.
Tumber, Anthony
Yapp, Clarence
Filippakopoulos, Panagis
Bunnage, Mark E.
Mueller, Susanne
Knapp, Stefan
Schofield, Christopher J.
Brennan, Paul E.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2014, 136 (26) : 9308 - 9319
[3] Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents
Chen, Qingjuan
Yang, Binhui
Liu, Xiaochen
Zhang, Xu D.
Zhang, Lirong
Liu, Tao
THERANOSTICS, 2022, 12 (11): : 4935 - 4948
[4] The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors
Wu, Xin
Zhang, Xin
Tang, Shaoshan
Wang, Yao
CELL BIOLOGY AND TOXICOLOGY, 2025, 41 (01)
[5] p300/CBP and cancer
Narayanan Gopalakrishna Iyer
Hilal Özdag
Carlos Caldas
Oncogene, 2004, 23 : 4225 - 4231
[6] Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors
Popp, Tobias A.
Tallant, Cynthia
Rogers, Catherine
Fedorov, Oleg
Brennan, Paul E.
Mueller, Susanne
Knapp, Stefan
Bracher, Franz
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (19) : 8889 - 8912
[7] Current development of CBP/p300 inhibitors in the last decade
He, Zhang-Xu
Wei, Bing-Fei
Zhang, Xin
Gong, Yun-Peng
Ma, Li-Ying
Zhao, Wen
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 209
[8] Designing p300/CBP histone acetyltransferase inhibitors for cancer
Cole, Philip A.
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
[9] Targeting cancer with selective cbp/p300 bromodomain inhibitors
Jaleel, Mahaboobi
Senaiar, Ramesh S.
Abbineni, Chandrasekhar
Renukappa, Girish A.
Mukherjee, Subhendu
Marappan, Sivapriya
Samiulla, D. S.
Aravind, A. B.
Kumar, Naveen R.
Reddy, Venkata Siva N.
Babu, Asha
Srinivas, Akhila P.
Yadlapalli, Prasad
Tgore, Suraj
Raghavendra, N. R.
Naik, Chandranath D.
Giri, Sanjeev
Antony, Thomas
Nellore, Kavitha
Chelur, Shekar
Daginakatte, Girish
Ravanti, laura
Myllymaki, Mikko
Wohlfahrt, Gerd
Mattila, Elina
Karlsson, Stefan
Bjorkman, Mari
Riikonen, Reetta
Ikonen, Tarja
Leimu, Laura
Malmstrom, Chira
Korjamo, Timo
Moilanen, Anu
Ramachandra, Murali
Samajdar, Susanta
CANCER RESEARCH, 2020, 80 (16)
[10] p300/CBP and cancer
Iyer, NG
Özdag, H
Caldas, C
ONCOGENE, 2004, 23 (24) : 4225 - 4231

← 1 2 3 4 5 →